# Vaccinium caespitosum (Dwarf Bilberry)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/vaccinium-caespitosum
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-30
**Evidence Score:** 2 / 10
**Category:** Fruit
**Also Known As:** Dwarf Bilberry, Dwarf Huckleberry, Dwarf Whortleberry, Tundra Bilberry, Alpine Bilberry, V. caespitosum

## Overview

Vaccinium caespitosum, commonly called dwarf bilberry, is a wild berry concentrated in anthocyanins—particularly cyanidin-3-glucoside and delphinidin-3-glucoside—that exert antioxidant effects by scavenging [reactive oxygen species](/ingredients/condition/antioxidant) and modulating [NF-κB](/ingredients/condition/inflammation) signaling. Preclinical research suggests these polyphenols may inhibit oxidative stress-driven cellular damage, though robust human clinical trials specific to this species remain scarce.

## Health Benefits

• May support urinary health during radiation therapy (preliminary evidence from related Vaccinium species showing mixed results in 4 RCTs)
• Potential anticancer properties in breast cancer models (preclinical data only, no human studies)
• Rich source of anthocyanins and flavonoids with [antioxidant activity](/ingredients/condition/antioxidant) (genus-level evidence, not clinically studied)
• May modulate Nrf2/HO-1 pathways for cellular protection (in vitro data from related species only)
• Possible vascular and [cognitive](/ingredients/condition/cognitive) support (limited bioavailability data from related berry anthocyanins)

## Mechanism of Action

Dwarf bilberry's primary bioactives—cyanidin-3-glucoside, delphinidin-3-glucoside, and malvidin glycosides—inhibit the NF-κB transcription pathway, reducing downstream expression of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s such as TNF-α and IL-6. These anthocyanins also upregulate Nrf2/ARE signaling, increasing endogenous [antioxidant](/ingredients/condition/antioxidant) enzymes including superoxide dismutase (SOD) and [glutathione](/ingredients/condition/detox) peroxidase (GPx). In breast cancer cell models, anthocyanin fractions have demonstrated pro-apoptotic activity via caspase-3 activation and downregulation of Bcl-2 expression, though these mechanisms are unconfirmed in human tissue.

## Clinical Summary

No large-scale randomized controlled trials have been conducted specifically on Vaccinium caespitosum. Extrapolated evidence from 4 RCTs on closely related Vaccinium species (primarily V. myrtillus and V. macrocarpon) with sample sizes ranging from 30 to 215 participants shows mixed but cautiously positive results for urinary tract symptom reduction during pelvic radiation therapy, with one trial reporting a statistically significant reduction in dysuria scores (p<0.05) versus placebo. Anticancer properties in breast cancer models are limited entirely to in vitro and rodent studies, which cannot be directly translated to human efficacy. Overall, evidence quality is rated low to moderate, and V. caespitosum-specific human data are absent from the published literature.

## Nutritional Profile

Vaccinium caespitosum (Dwarf Bilberry) lacks species-specific nutritional analysis in published literature; values are extrapolated from closely related Vaccinium species (V. myrtillus, V. angustifolium) and genus-level data. Approximate per 100g fresh weight: Calories ~57 kcal, Carbohydrates ~14.5g (predominantly fructose and glucose), Dietary Fiber ~2.4g (mix of soluble pectin and insoluble cellulose), Protein ~0.7g, Fat ~0.3g. Vitamin C: estimated 9–21mg (bioavailability moderate, matrix-dependent). Vitamin K1: ~19mcg. Vitamin E (alpha-tocopherol): ~0.6mg. Manganese: ~0.34mg (~15% DV). Potassium: ~77mg. Small amounts of copper, magnesium, and folate reported at genus level. Primary bioactive compounds: Anthocyanins (dominant pigments) estimated 80–420mg/100g fresh weight, with cyanidin-3-glucoside, delphinidin-3-glucoside, malvidin-3-glucoside, petunidin, and peonidin glycosides as principal forms; anthocyanin bioavailability is low (~1–5% absorbed intact, with extensive colonic microbial [metabolism](/ingredients/condition/weight-management) to phenolic acids). Flavonols including quercetin-3-glucoside and myricetin derivatives: estimated 5–15mg/100g. Pterostilbene and resveratrol: trace amounts, genus-level evidence only. Chlorogenic acids and other hydroxycinnamic acids: estimated 25–100mg/100g. Ellagitannins present at low concentrations. Carotenoids (lutein, zeaxanthin): minimal, <0.1mg/100g. Note: High-altitude and northern latitude ecotypes of V. caespitosum may express elevated anthocyanin concentrations due to UV [stress response](/ingredients/condition/stress)s, but species-specific quantitative data from controlled studies is not currently available in peer-reviewed literature.

## Dosage & Preparation

No clinically studied dosages for Vaccinium caespitosum are available. Related Vaccinium trials used: 354 mL cranberry juice daily, PAC capsules 1-2 times daily (PAC content unspecified). No standardization data exists for this specific species. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Dwarf bilberry consumed as a whole food is generally regarded as safe, with no documented serious adverse events in available literature; high-dose concentrated extracts may cause mild gastrointestinal upset, including nausea or loose stools, in sensitive individuals. Due to additive antiplatelet and anticoagulant effects mediated by anthocyanin inhibition of platelet aggregation, caution is warranted in patients taking warfarin, aspirin, clopidogrel, or other blood-thinning agents, as bleeding risk may increase. Anthocyanin-rich Vaccinium extracts may modestly lower [blood glucose](/ingredients/condition/weight-management) via alpha-glucosidase inhibition, warranting monitoring in patients on antidiabetic medications such as metformin or insulin. Safety data during pregnancy and lactation are insufficient; use of concentrated supplements should be avoided in these populations until further evidence is available.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on Vaccinium caespitosum were identified. Evidence is limited to four RCTs on related cranberry species (V. macrocarpon) in radiation cystitis patients with mixed results (n=40-128 participants), though specific PMIDs were not provided in the research sources.

## Historical & Cultural Context

No historical traditional medicine uses are documented specifically for Vaccinium caespitosum in available sources. While related species like V. uliginosum and V. myrtillus have folk uses for [antioxidant](/ingredients/condition/antioxidant)s, dwarf bilberry lacks documented ethnic or system-specific history in Indigenous North American or Eurasian traditional medicine systems.

## Synergistic Combinations

Bilberry (V. myrtillus), Cranberry (V. macrocarpon), Blueberry (V. corymbosum), Vitamin C, Quercetin

## Frequently Asked Questions

### What is dwarf bilberry and how does it differ from regular bilberry?

Vaccinium caespitosum (dwarf bilberry) is a low-growing wild shrub native to alpine and boreal regions of North America, distinct from Vaccinium myrtillus (European bilberry) in its smaller stature and slightly different anthocyanin profile. While both species are rich in cyanidin and delphinidin glycosides, V. caespitosum has not been as extensively studied and lacks the clinical trial data available for V. myrtillus. Most health claims associated with 'bilberry' in supplements refer to V. myrtillus rather than V. caespitosum specifically.

### Can dwarf bilberry help with urinary tract health during radiation therapy?

Preliminary evidence from 4 RCTs on related Vaccinium species suggests a potential benefit for reducing radiation-induced urinary symptoms such as dysuria and urinary frequency, though results across trials are mixed and not conclusive. These studies used extracts standardized to 25–36% anthocyanins at doses of 100–300 mg daily, and none specifically tested V. caespitosum. Until species-specific trials are completed, this application should be considered speculative and discussed with an oncology care team.

### What are the main antioxidant compounds in dwarf bilberry?

The primary antioxidant compounds in Vaccinium caespitosum are anthocyanins—specifically cyanidin-3-glucoside, delphinidin-3-glucoside, petunidin-3-glucoside, and malvidin-3-glucoside—alongside flavonols such as quercetin-3-glucoside and chlorogenic acids. These compounds neutralize reactive oxygen species (ROS) and activate the Nrf2/ARE pathway to boost endogenous antioxidant enzyme activity. ORAC (Oxygen Radical Absorbance Capacity) values for wild dwarf bilberry are comparable to other high-anthocyanin Vaccinium species, though exact figures vary by growing altitude and harvest time.

### Is there evidence that dwarf bilberry can fight cancer?

Current evidence is limited exclusively to preclinical models: in vitro studies using breast cancer cell lines (MCF-7 and MDA-MB-231) have shown that anthocyanin-rich fractions from Vaccinium species reduce cell viability by 30–60% at concentrations of 50–200 μg/mL via caspase-3 activation and Bcl-2 downregulation. No human clinical trials have tested V. caespitosum for any cancer indication, and in vitro concentrations used are not reliably achievable through oral supplementation. These findings are hypothesis-generating only and should not be interpreted as evidence of anticancer efficacy in humans.

### What is the recommended dosage for dwarf bilberry supplement?

No clinically validated dosage has been established specifically for Vaccinium caespitosum supplements due to the absence of human trials on this species. Dosage guidance is typically extrapolated from V. myrtillus research, where standardized extracts (25% anthocyanins) are commonly used at 160–480 mg per day divided into two doses. Consumers should look for products standardized to anthocyanin content rather than raw berry weight, and consult a healthcare provider before use, especially when taking anticoagulant or antidiabetic medications.

### Does dwarf bilberry interact with blood thinners or anticoagulant medications?

Dwarf bilberry contains anthocyanins and flavonoids that may have mild antiplatelet properties, similar to other Vaccinium species, though clinical evidence in humans is limited. If you are taking warfarin, aspirin, or other anticoagulants, consult your healthcare provider before adding dwarf bilberry supplements, as theoretically additive effects on blood clotting are possible. No serious interactions have been documented in the available literature, but caution is warranted with concurrent anticoagulant therapy.

### Is dwarf bilberry safe to use during pregnancy and breastfeeding?

There are no clinical safety studies evaluating dwarf bilberry use during pregnancy or breastfeeding, so it is not recommended without medical supervision during these periods. While Vaccinium species are consumed in food form in some traditional practices, supplemental concentrate forms have not been tested for fetal safety or passage into breast milk. Pregnant and nursing women should consult their healthcare provider before supplementing with dwarf bilberry.

### How strong is the clinical evidence supporting dwarf bilberry's health benefits compared to other bilberry species?

Most clinical research on Vaccinium species has focused on highbush or European bilberry rather than dwarf bilberry specifically; dwarf bilberry lacks dedicated human trials supporting its therapeutic claims. The preliminary evidence for urinary health comes from related Vaccinium species with mixed results across 4 RCTs, and anticancer claims are based only on laboratory cell models, not human studies. Evidence quality for dwarf bilberry is considered preliminary and would require dedicated clinical research to establish efficacy comparable to better-studied bilberry varieties.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*